This case follows the journey of Amyris Biotechnologies from being one of the most popular clean tech startups in Silicon Valley to being an out-of-favor public company. This case explores the difficulties of changing a high capex business model and asks students to evaluate the best market for the company to apply a technology to. Students have to weigh the value of going after larger markets solving major problems for society versus focusing on short-term profitability. The case also addresses the challenges of being a mission-driven organization. There were many benefits for Amyris to being a company focused on curing malaria and then finding renewable fuel sources, but the mission could be seen as a disadvantage when trying to shift the focus to high-value chemicals such as cosmetics.